Please login to the form below

Not currently logged in

Takeda expands into Brazil

Takeda, Japan's largest drug company, has announced it is to establish a commercial subsidiary in Brazil

Takeda, Japan's largest drug company, has announced it is to establish a commercial subsidiary in Brazil.

The new operation, which will be based in Sao Paulo, will import and commercialise Takeda products for the Brazilian market.

This latest expansion by the Japanese company is the twelfth in as many months following the establishment of subsidiaries in Belgium, Canada, Denmark, Ireland, Luxembourg, Mexico, Norway, Portugal, Spain, Sweden and Turkey.

"Combined with Takeda's additional recent expansions, this opportunity will drive Takeda's ability to maximise the potential of our pipeline in Brazil," said Alan MacKenzie, executive vice president international operations, Takeda Pharmaceuticals International.

"Brazil is an important country in the Latin American region for Takeda to ensure we are providing our products where patients need them."

With a population of around 196 million people, Brazil is the largest country in Latin America and accounts for more than 40 per cent of pharmaceutical sales in the region. Pharmaceutical sales in the country are forecast to grow by 8.5 per cent each year until 2013.

2nd December 2009


Featured jobs

Subscribe to our email news alerts


Add my company
Syneos Health™

Syneos Health™ is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract...

Latest intelligence

How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...
Medopad: the up and coming unicorn transforming remote patient monitoring
Blue Latitude Health speaks to Medopad’s Martha Carruthers to learn how the start-up’s modular apps are helping patients with complex diseases....